Want to see AU:ATX full AI Analyst Report?
ATX Stock Chart & Stats
AU$0.14
<AU$0.01(2.33%)
At close: 4:00 PM EST
AU$0.14
<AU$0.01(2.33%)
Day’s Range― - ―
52-Week RangeAU$0.10 - AU$0.43
Previous CloseN/A
Volume274.48K
Average Volume (3M)525.22K
Market Cap
AU$77.00M
Enterprise ValueAU$34.08M
Total Cash (Recent Filing)AU$27.85M
Total Debt (Recent Filing)AU$341.11K
Price to Earnings (P/E)―
Beta0.07
Next Earnings
Nov 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding513,312,000
10 Day Avg. Volume444,673
30 Day Avg. Volume525,217
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)2.80
Price to Sales (P/S)0.00
P/FCF Ratio-12.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance-sheet CushionA sizable equity cushion (equity ≈39.5M of ~41.4M assets) and historically low leverage materially reduce short-term insolvency risk, giving management flexibility to fund clinical programs, negotiate partnerships, or manage timing of financing without immediate distress.
Focused R&D PipelineA concentrated R&D strategy centered on FAK with a clear lead candidate (AMP945) narrows scientific risk and concentrates resources. This focus can improve trial design efficiency, attract targeted partnerships, and create a single high-value development path if clinical data are positive.
High Gross Margins HistoricallyPrior periods showed strong gross margins when revenue was present, suggesting the company’s offerings or licensing could support attractive unit economics. High potential margins improve scalability and the ability to fund operations or reinvest in R&D after commercialization.
Bears Say
No Recent Revenue; Persistent LossesZero revenue in the latest year combined with recurrent and widening losses signals lack of commercial validation and ongoing reliance on external capital. This elevates dilution risk and constrains strategic optionality, making progress contingent on successful financing or partnerships.
Worsening Cash BurnConsistent negative operating and free cash flow, with cash burn increasing year-over-year, shortens runway and forces near-term capital raises or partnership deals. That pressure can delay programs, trigger unfavorable financing terms, and heighten execution risk for clinical milestones.
Very Small HeadcountA team of eight limits internal capacity to manage complex trials, regulatory filings, and commercialization preparations. Heavy reliance on external contractors or partners raises coordination risk, can slow timelines, and may increase per-milestone costs as programs scale.
Amplia Therapeutics News
ATX FAQ
What was Amplia Therapeutics Ltd.’s price range in the past 12 months?
Amplia Therapeutics Ltd. lowest share price was AU$0.10 and its highest was AU$0.42 in the past 12 months.
What is Amplia Therapeutics Ltd.’s market cap?
Amplia Therapeutics Ltd.’s market cap is AU$77.00M.
When is Amplia Therapeutics Ltd.’s upcoming earnings report date?
Amplia Therapeutics Ltd.’s upcoming earnings report date is Nov 25, 2026 which is in 145 days.
How were Amplia Therapeutics Ltd.’s earnings last quarter?
Amplia Therapeutics Ltd. released its earnings results on May 29, 2026. The company reported -AU$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.007.
Is Amplia Therapeutics Ltd. overvalued?
According to Wall Street analysts Amplia Therapeutics Ltd.’s price is currently Overvalued.
Does Amplia Therapeutics Ltd. pay dividends?
Amplia Therapeutics Ltd. does not currently pay dividends.
What is Amplia Therapeutics Ltd.’s EPS estimate?
Amplia Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Amplia Therapeutics Ltd. have?
Amplia Therapeutics Ltd. has 513,312,000 shares outstanding.
What happened to Amplia Therapeutics Ltd.’s price movement after its last earnings report?
Amplia Therapeutics Ltd. reported an EPS of -AU$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Amplia Therapeutics Ltd.?
Currently, no hedge funds are holding shares in AU:ATX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Amplia Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:ATX Sentiment 96%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
66.66%
12-Months-Change
Fundamentals
Return on Equity
-18.71%
Trailing 12-Months
Asset Growth
98.58%
Trailing 12-Months
Company Description
Amplia Therapeutics Ltd.
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Technical Analysis
Tryptamine Therapeutics
―
Neuren Pharmaceuticals Limited
―
Paradigm Biopharmaceuticals
―
Alterity Therapeutics
―
Zelira Therapeutics
―
Options Prices
Currently, No data available
---